Featured Research

from universities, journals, and other organizations

Protein molecule may improve survival in deadly lung disease

Date:
May 6, 2014
Source:
University of Illinois at Chicago
Summary:
A protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis, has been discovered by researchers. Nearly five million people worldwide are affected by pulmonary fibrosis, which causes the lungs to become covered in fibrous scar tissue and leads to shortness of breath that gets more severe as the disease progresses.

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.

The finding is reported in the American Journal of Respiratory and Critical Care Medicine.

Nearly five million people worldwide are affected by pulmonary fibrosis, which causes the lungs to become covered in fibrous scar tissue and leads to shortness of breath that gets more severe as the disease progresses.

Chronic inflammatory and autoimmune diseases can cause pulmonary fibrosis, as can exposure to asbestos, certain toxic gases, and even radiation therapy to treat lung cancer. Treatment options are limited because once scarring occurs, it is permanent. Lung transplantation remains the only effective treatment, but it is usually reserved for advanced cases.

"Finding a new therapeutic target for the treatment of pulmonary fibrosis is exciting, especially because the therapies available generally only slow the disease in very few patients," said Long Shuang Huang, UIC postdoctoral research associate in pharmacology and first author of the paper.

In previous genetic studies of patients with idiopathic pulmonary fibrosis -- where no cause can be identified -- the researchers found variations in several genes known to be involved in pulmonary fibrosis, including in the gene coding for a protein called lysocardiolipin acyltransferase, or LYCAT.

To investigate the potential role of LYCAT in pulmonary fibrosis, the researchers measured its levels in the blood of idiopathic pulmonary fibrosis patients. Patients with the highest levels of LYCAT had significantly better lung function and higher three-year survival rates than those with lower levels.

"Since higher LYCAT levels directly correlate with better lung function and outcomes, we think the protein is playing some kind of protective role, or could be slowing the progress of pulmonary fibrosis," Huang said. "This suggests that boosting LYCAT levels in patients with pulmonary fibrosis may be a viable new therapeutic approach to treating the disease," Huang said.

The researchers also looked at the role of LYCAT in a mouse model of lung tissue scarring, and found that in mice where the LYCAT gene was knocked out, scar tissue developed more readily compared to mice with the gene. In mice engineered to produce elevated levels of LYCAT the development of scarring was much slower.

Looking for compounds or small molecules that increase the production of LYCAT is the next step for Huang and his colleagues.


Story Source:

The above story is based on materials provided by University of Illinois at Chicago. The original article was written by Sharon Parmet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Long Shuang Huang, Biji Mathew, Haiquan Li, Yutong Zhao, Shwu-Fan Ma, Imre Noth, Sekhar P. Reddy, Anantha Harijith, Peter V. Usatyuk, Evgeny V. Berdyshev, Naftali Kaminski, Tong Zhou, Wei Zhang, Yanmin Zhang, Jalees Rehman, Sainath R. Kotha, Travis O. Gurney, Narasimham L. Parinandi, Yves A. Lussier, Joe G.N. Garcia, Viswanathan Natarajan. The Mitochondrial Cardiolipin Remodeling Enzyme Lysocardiolipin Acyltransferase (LYCAT) is a Novel Target in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014; 140429121011006 DOI: 10.1164/rccm.201310-1917OC

Cite This Page:

University of Illinois at Chicago. "Protein molecule may improve survival in deadly lung disease." ScienceDaily. ScienceDaily, 6 May 2014. <www.sciencedaily.com/releases/2014/05/140506130435.htm>.
University of Illinois at Chicago. (2014, May 6). Protein molecule may improve survival in deadly lung disease. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/05/140506130435.htm
University of Illinois at Chicago. "Protein molecule may improve survival in deadly lung disease." ScienceDaily. www.sciencedaily.com/releases/2014/05/140506130435.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins